Phenotypic characterization of severe asthma

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 1, 2010, Pages 48-54

  Ogawa, Yoshiko ^a   Calhoun, William J ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHITINASE; CORTICOSTEROID; INTERLEUKIN 13; LIPOXIN; NITRIC OXIDE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPY; COST BENEFIT ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; LUNG FUNCTION; PHENOTYPE; REVIEW;

ASTHMA; BIOLOGICAL MARKERS; CHITINASE; HUMANS; INTERLEUKIN-13; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 74549204150     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283357d15     Document Type: Review

References (25)

1. Wenzel SE, Busse WW, for the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:14-21.
2. Moore WC, Bleecker ER, Curran-Everett D, et al., for the National Heart, Lung, Blood Institute's Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405-413.
3. Trends in asthma morbidity and mortality. American Lung Association. Epidemiology and Statistics Unit, Research and Program Services; January 2009.
4. Teeter JG, Bleecker ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998; 113:272-277.
5. Boulet LP, Phillips R, O'Byrne P, Becker A. Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can Respir J 2002; 9:417-423.
6. Wolfenden LL, Diette GB, Krishnan JA, et al. Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Intern Med 2003; 163:231-236.
7. Miller MK, Johnson C, Miller DP, et al., for the TENOR Study Group. Severity assessment in asthma: an evolving concept. J Allergy Clin Immunol 2005; 116:990-995.
8. The ENFUMOSA cross-sectional European multicenter study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22:470-477.
9. Moore WC, Peters SP. Severe asthma: an overview. J Allergy Clin Immunol 2006; 117:487-494.
10. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113:101-108.
11. Jenkins HA, Cherniack R, Szefler SJ, et al. A comparison of the clinical characteristics of children and adults with severe asthma. Chest 2003; 124:1318-1324.
12. Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol 1998; 101:594-601.
13. Dolan CN, Fraher KE, Bleecker ER, et al. for TENOR StudyGroup. Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92:32-39.
14. Ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744-748.
15. Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24:122-128.
16. Berry MA, Shaw DE, Green RH, et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005; 35:1175-1179.
17. Payne DN, Adcock IM, Wilson NM, et al. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma after treatment with oral prednisone. Am J Respir Crit Care med 2001; 164:1376-1381.
18. Silkoff PE, Lent AM, Busacker AA, et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005; 116:1249-1255.
19. Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008; 121:685-691.
20. Starosta V, Pazdrak K, Boldogh I, et al. Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes. J Immunol 2008; 181:8688-8699.
21. 21Planaguma A, Kazani S, Marigowda G, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008; 178:574-582.
22. Hong JH, Hong JY, Park B, et al. Chitinase activates protease-activated receptor-2 in human airway epithelial cells. Am J Respir Cell Mol Biol 2008; 39:530-535.
23. Chupp GL, Lee CG, Jarjour N, et al. A Chitinase-like protein in the lung and circulation of patients with severe asthma. N Eng J Med 2007; 357:2016-2027.
24. Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma and lung function. N Eng J Med 2008; 358:1682-1691.
25. Brasier AR, Victor S, Boetticher GD, et al. Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immun 2008; 121:30-37.